All In Biotech

Drug Trial Radar · NCT04675151

Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) With Pilocarpine Eye Drops in Subjects With Presbyopia

Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

150

Actual

Start

Feb 15, 2021

Primary completion

May 17, 2021

Study completion Jun 30, 2021

Sponsor

Lead sponsor
Opus Genetics, IncIndustry
Sponsor type
Industry
First posted
Dec 19, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objectives of this study are: To evaluate the efficacy of Nyxol + Pilocarpine to improve DCNVA in subjects with presbyopia

Conditions

  • Presbyopia

Interventions

  • Phentolamine Ophthalmic Solution 0.75%Drug

    0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist

  • PilocarpineDrug

    Pilocarpine ophthalmic solution

  • PlaceboOther

    Topical sterile ophthalmic solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent of Subjects With ≥ 15 Letters of Improvement in Photopic Binocular DCNVATime frame: Visit 2 at 1 hour

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Site 12

    Laguna Hills, California

  • Clinical Site 6

    Newport Beach, California

  • Clinical Site 13

    Crystal River, Florida

  • Clinical Site 5

    Longwood, Florida

  • Clinical Site 11

    Maitland, Florida

  • Clinical Site 8

    Sarasota, Florida

  • Clinical Site 10

    Roswell, Georgia

  • Clinical Site 3

    Pittsburg, Kansas

  • Clinical Site 18

    St Louis, Missouri

  • Clinical Site 16

    Poughkeepsie, New York

  • Clinical Site 14

    Fargo, North Dakota

  • Clinical Site 2

    Athens, Ohio

  • Clinical Site 9

    Cincinnati, Ohio

  • Clinical Site 7

    Cleveland, Ohio

  • Clinical Site 15

    Powell, Ohio

  • Clinical Site 4

    Warwick, Rhode Island

  • Clinical Site 1

    Memphis, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.